Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cyclacel Reaches Agreement With FDA

September 13, 2010 8:53 am | News | Comments

Cyclacel Pharmaceuticals Inc. said it has reached a deal with the Food and Drug Administration on a design for a late-stage study of a potential cancer treatment and plans to begin patient enrollment before the end of 2010.


Mystery of Protein Quality Control Unraveled

September 13, 2010 8:39 am | News | Comments

Scientists have solved a long-standing mystery of how cells conduct "quality control" to eliminate the toxic effects of a certain kind of error in protein production. The findings may lead to a better understanding of a host of neurodegenerative diseases.


Gene Discovery Could Yield Treatment for Nearsightedness

September 13, 2010 8:37 am | News | Comments

Scientists at Duke University Medical Center, in conjunction with several other groups, have uncovered a gene associated with myopia in Caucasian people from several different regions, including Dutch, British and Australian subjects.


Melanoma Drug Data to Be Presented At IMRC

September 13, 2010 8:15 am | News | Comments

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the International Melanoma Research Congress.


Phase 2 Studies Confirm Radezolid Effectiveness

September 13, 2010 8:09 am | News | Comments

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, announced the presentation of positive preclinical data for radezolid at the Interscience Conference on Antimicrobial Agents and Chemotherapy.


LabCorp to Buy Genzyme Genetic Testing Business

September 13, 2010 8:04 am | News | Comments

Genzyme Corp. said that it is selling its genetic testing business to Laboratory Corp. of America Holdings for $925 million so it can focus on its core growth areas.


FDA Considers Pulling Dangerous Diet Pill

September 13, 2010 8:01 am | by Matthew Perrone | News | Comments

Almost a year after studies showed the diet pill Meridia increases heart attack and stroke risk, U.S. health regulators announced they will consider pulling the Abbott Laboratories' drug off the market.


Limber LIMS

September 13, 2010 7:57 am | Articles | Comments

A range of Web-based tools are bringing automated management to more labs.


DDI Reality via Virtual Studies

September 13, 2010 7:41 am | by Steve Toon, PhD; Executive Director; Elizabeth Kingsley, PhD; PR Coordinator; Simcyp Limited; Sheffield, UK | Articles | Comments

Simulation of drug-drug interactions anticipate in vivo outcomes.


Shedding A New Light on GPCRs

September 13, 2010 7:08 am | by Jean-Luc-Tardieu, PhD; Product Manager; Cisbio Bioassays; Bagnols-sur-Cèze, France | Articles | Comments

Fluorescent assay methods aid GPCR investigation in the discovery and development of therapeutic antibodies.


ADME Picks Up Speed

September 13, 2010 6:49 am | by Alan Dove, PhD, Contributing Editor | Articles | Comments

Pharmacokinetic assays have traditionally been a bottleneck in lead optimization, but a new generation of technologies is increasing the throughput of these critical tests.


Cell Migration and Invasion Assay

September 10, 2010 8:19 am | Product Releases | Comments

TTP LabTech has joined forces with Platypus Technologies to offer automated solutions for studying the migration and invasion profiles of different cell lines using the Acumen eX3 laser scanning microplate cytometer.


Bausch + Lomb Pharma Appoints New President

September 10, 2010 7:55 am | News | Comments

Bausch + Lomb, the global eye health company, has named Daniel M. Wechsler as corporate vice president and global president of its Pharmaceuticals business.


Sanofi Denies Raising Genzyme Offer

September 10, 2010 7:51 am | News | Comments

French drugmaker Sanofi-Aventis SA is sticking to its original offer of $69 a share to buy U.S. biotech company Genzyme Corp., according to a Sanofi spokesman.


Metastatic Melanoma Treatment Fast-Tracked By FDA

September 10, 2010 7:34 am | News | Comments

In a phase 3 study, researchers randomly assigned patients to one of three treatment groups: those receiving ipilimumab plus an inactive version of gp 100 (a cancer vaccine); those receiving ipilimumab plus gp 100; and those receiving gp 100 plus ipilimumab placebo.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.